31 RESULTS
COMMENT In this paper, the authors conducted an interesting secondary analysis of CSF and longitudinal tau PET data from ADNI. CSF levels of GAP-43, a presynaptic protein important in neurodevelopment and in axonal regeneration, are increased in MCI and AD, and h
COMMENT Protein biomarkers for Parkinson’s disease and DLB have been sought extensively, with far fewer hits than in AD. Recent efforts using the O-link multiplex immune-PCR assay system for discovery have yielded interesting results. In a large, multicenter CSF
COMMENT The remarkable ability of seed amplification assays (SAA), such as RT-QuIC, to detect pathological α-synuclein in CSF has enabled many interesting clinical questions to be addressed, in particular, those related to early diagnosis of synuclein disorders.
COMMENT This is a remarkable study by design, with extraordinary rigorous attention to detail and definition of genomic properties of cell lines to identify as neutral a cell line as is possible. The proposed reference cell line will be extremely useful to compar
COMMENT Steve Wagner, who passed away on March 12, 2022, after a sudden illness, is deeply mourned by friends and colleagues at UCSD, his academic home for the past decade, and by the many people whose lives he touched. Steve trained in biochemistry and cell biol
COMMENT I have greatly valued John’s enormous contributions in the field of molecular neuropathology relevant to Alzheimer’s and had the privilege of collaborating with him on several projects over the years. One of these areas was ALS-PDC of Guam, where John ana
COMMENT This is an extremely helpful initiative that will have a huge impact on iPSc research in relation to AD and other neurodegenerative disorders. There are many advantages to studying human neurons and glial cells as models for these disorders. Rodent models
COMMENT I am a paid consultant for Biogen, so will not comment directly on the FDA’s deliberation of aducanumab. I raise here some general questions that may have an impact on AD therapeutics going forward as we are all taking stock of where we are with the data
COMMENT The COVID-19 pandemic has had a tremendous impact on human subjects research in which I am involved. Our overarching policy is that we need to minimize risk for study participants and research staff. We also are cognizant of resource utilization, e.g., ke
COMMENT These trial reanalyses look promising and have certainly rekindled enthusiasm for the amyloid hypothesis. I am a site investigator in one of these Biogen trials, hence will only comment in general terms because there may be efforts to re-enroll subjects.
COMMENT I have not seen the announcement, but my general comments relate to two questions: target and tools. For tau passive immunotherapy, the antibody would need to reach its target of a tau seed or a misfolded form of tau in sufficient amount to make a differe
COMMENT I read this paper with interest. There are many substrates besides VCAM1 that might be altered as a result of BACE-2 inhibition, with potentially unknown effects on the brain. The magnitude of alteration was clearly higher in the presence of TNF-α, which
COMMENT This plasma assay used IP-MS methodology, with standardization of plasma levels of Aβ42, 40, and a novel peptide by inclusion of Aβ38. The assay methods are well described, and the CV’s for the various plasma measures were low (around 5 percent). There wa
COMMENT The study of NfL in autosomal-dominant AD (ADAD) provides exciting preliminary evidence supporting this as a progression marker. The effect size was much more impressive in symptomatic patients than in preclinical carriers, and it will be interesting to s
COMMENT Neurogranin appears to be an interesting and novel marker that appears to reflect post-synaptic damage. There are multiple proteolytically cleaved forms of neurogranin in CSF; this is reminiscent of tau, with which neurogranin correlates. It is possible t
